Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of HJB647 in healthy participants and otherwise healthy participants with elevated blood pressure
NL-OMON59893Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HJB647 in heart failure (HF) (3 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started Nov 2023; status: completed.
02
Drugs
HJB647
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON59893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59893.